Proglumide

CAT: 804-HY-B1330-01Size: 50 mgDry Ice: NoHazardous: No
50 mgSelected
AVAILABILITY
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Proglumide is a nonpeptide and orally active cholecystokinin (CCK) -A/B receptors antagonist. Proglumide selective blocks CCK’s effects in the central nervous system (CNS) . Proglumide has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide also has antiepileptic and antioxidant activities[1][2][3][4][5].
CAS Number
[6620-60-6]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Cholecystokinin Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Cancer-programmed cell death
Field of Research
Cancer; Endocrinology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/Proglumide.html
Concentration
10mM
Purity
99.84
Solubility
DMSO : ≥ 65 mg/mL
Smiles
O=C(O)CCC(NC(C1=CC=CC=C1)=O)C(N(CCC)CCC)=O
Molecular Formula
C18H26N2O4
Molecular Weight
334.41
Precautions
H302, H315, H319, H335
References & Citations
[1]Ahmad M, et al. The effects of quinacrine, proglumide, and pentoxifylline on seizure activity, cognitive deficit, and oxidative stress in rat lithium-pilocarpine model of status epilepticus. Oxid Med Cell Longev. 2014;2014:630509.|[2]Iwamoto Y, et al. In vitro and in vivo effect of proglumide on cholecystokinin-stimulated amylase release in mouse pancreatic acini. Gastroenterol Jpn. 1984 Feb;19 (1) :53-8.|[3]González-Puga C, et al. Selective CCK-A but not CCK-B receptor antagonists inhibit HT-29 cell proliferation: synergism with pharmacological levels of melatonin. J Pineal Res. 2005 Oct;39 (3) :243-50.|[4]Bunney BS, et al. Further studies on the specificity of proglumide as a selective cholecystokinin antagonist in the central nervous system. Ann N Y Acad Sci. 1985;448:345-51.|[5]Tariq M, et al. Gastric and duodenal antiulcer and cytoprotective effects of proglumide in rats. J Pharmacol Exp Ther. 1987 May;241 (2) :602-7.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched

Related Products

CatalogName